Biosimilars for the next decade in Latin America: a window of opportunity
Author:
- 3 August 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (8) , 659-669
Abstract
Biosimilars are gaining popularity in Latin America (LA). The biosimilars market is expected to grow rapidly over the next decade as a cost-effective alternative to expensive patented biologics. The drivers for the growing demand include needs for affordable health care, the prevalence of chronic diseases, expiration of patents for numerous biologic medicines and the advent of artificial intelligence (AI). Countries such as Argentina, Brazil and Mexico have implemented regulatory frameworks for the approval of biosimilars as well as for investment in local manufacturing capacity, sale, and distribution. Some LA countries face challenges related to low quality institutional frameworks and deficient public policies for regulatory harmonization of these medicines. The aim of this article is to analyze the broad window of opportunity for biosimilars in LA (Brazil, Mexico and Argentina) in the next decade, considering their regulations and institutional quality, as well as an affordable cost for patients with chronic diseases and highlight the biosimilars approved in the three countries studied. Likewise, the future contribution of AI in the drug R&D process is considered. Preparing the next decade of biosimilars in LA will involve improving international regulatory frameworks, institutional quality, investments and capacity in R&D (competencies, infrastructure, and AI).Keywords
This publication has 67 references indexed in Scilit:
- Dynamic catch-up strategy, capability expansion and changing windows of opportunity in the memory industryResearch Policy, 2017
- Catch-up cycles and changes in industrial leadership:Windows of opportunity and responses of firms and countries in the evolution of sectoral systemsResearch Policy, 2017
- Location Advantages, Governance Quality, Stock Market Development and Firm Characteristics as Antecedents of African M&AsJournal of International Management, 2016
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016
- Good governance: a new perspective for institutional reform - a comparative view of water, education and health institutions in EgyptInternational Journal of Public Policy, 2016
- Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin AmericaBiotechnology Advances, 2013
- Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for IndustryBiotechnology Law Report, 2013
- Potential Regulatory and Commercial Environment for Biosimilars in Latin AmericaValue in Health Regional Issues, 2012
- Technological regimes, catching-up and leapfrogging: findings from the Korean industriesResearch Policy, 2001
- Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industryInternational Journal of Industrial Organization, 2000